Diagnostic value of cystatin C in patients with drug-resistant pulmonary tuberculosis receiving palliative care
DOI:
https://doi.org/10.14739/2310-1210.2019.2.161488Keywords:
drug-resistant tuberculosis, palliative care, cystatin CAbstract
To date there are no data on the study of heart failure early diagnostic criteria in patients with pulmonary drug-resistant tuberculosis (DRTB) available in the literature.
The purpose of the work is to determine the level of serum cystatin C in patients with pulmonary DRTB receiving palliative care and to establish the diagnostic value of this indicator in the early diagnosis of heart failure.
Materials and methods. Patients of the main group received palliative care were divided into 2 groups depending on the body mass index (BMI): the main group 1 consisted of 26 patients with BMI ≤18.1 kg/m2, the main group 2 was composed of 26 patients with BMI >18.1 kg/m2. The control group included 29 patients who received antimycobacterial therapy by category 4 according to the drug resistance profile. The level of serum cystatin C was measured by an enzyme-linked immunosorbent assay (ELISA) using the kit “Human Cystatin C ELISA BioVendor Research and Diagnostic Products” (ng/ml; Czech Republic). The serum level of TNF-α was studied by ELISA in a reader Sirio S using the kit “Bender MedSystems GmbH” (Austria), (pkg/ml). The results of the study were processed on a personal computer using statistical software package Statistica, version 13 (Copyright 1984–2018 TIBCO Software Inc. All Rights reserved. License No. JPZ8041382130ARCN10-J).
Results. In patients with pulmonary DRTB receiving antimycobacterial therapy, the level of cystatin C exceeds the upper limit of the normal reference values, and in palliative care DRTB patients with BMI >18.1 kg/m2 it is 10,4 % higher than in pulmonary DRTB patients receiving antimycobacterial therapy. At the same time, in patients with pulmonary DRTB receiving antimycobacterial therapy, an increase in serum cystatin C level is significantly associated with a decrease in serum TNFα levels and an increase in BMI. In palliative care patients with DRTB and BMI >18.1 kg/m2, an increase in serum cystatin C levels significantly depends directly on a decrease in serum TNFα. And in palliative care patients with pulmonary DRTB and BMI ≤18.1 kg/m2, a decrease in cystatin C level significantly depends directly on a decrease in BMI and inversely depends on an increase in serum TNFα level, which leads to a significant decrease in the overall quality of life score and heart failure progression.
Conclusions. In palliative care patients with DRTB and BMI >18.1 kg/m2, increased level of cystatin C can serve as an early marker of heart failure development. In palliative care patients with DRTB and BMI ≤18.1 kg/m2, low level of cystatin C can serve as a marker of secondary cardiovascular disease development and heart failure progression.
References
Voronenko, Yu. V., Gubskiy, Yu. I., & Tsarenko, A. V. (2014). Stvorennia systemy palіativnoi ta hospіsnoi dopomohy v umovakh reformuvannia okhorony zdorovia v Ukrainі: medychnі ta sotsіalnі aspekty [Creating of the hospice and palliative care system in the conditions of health care reform in ukraine: medical and social aspects]. Nauka і praktyka. Mіzhvіdomchyi medychnyi zhurnal, 1(2), 63–75. [in Ukrainian].
Raznatovskaya, E. N. (2013). Analiz prichin smerti bol'nykh khimiorezistentnym tuberkulezom legkikh [Analysis of causes of death in patients with resistant pulmonary tuberculosis]. Klinicheskaya infektologiya i parazitologiya, 2(05), 29–39. [in Russian].
Bilovol, А. N., Mykhailova, Yu. А., Petyunina, O.V., & Lapshina, L. A. (2012). Osobennosti kardiogemodinamiki, izmenenij markerov disfunkcii pochek i citokinogeneza pri khronicheskoj serdechnoj nedostatochnosti i khronicheskoj serdechnoj nedostatochnosti v sochetanii s khronicheskoj bolezn'yu pochek [The peculiarities of cardiac hemodynamics, changes of markers of kidney dysfunction and immune inflammation in chronic heart failure and in chronic heart failure accompanied by chronic kidney disease]. Ukrainskyj terapevtychnyj zhurnal, 3–4, 20–25. [in Russian].
Velkov, V. V. (2011). Cistatin S – novye vozmozhnosti i novye zadachi dlya laboratornoj diagnostiki [Cystatin C: the new opportunities and new goals for laboratory diagnostics (part 3)]. Laboratornaya diagnostika, 2(56), 31–37. [in Russian].
Alehagen, U., Dahlström, U. Lindahl, T. L. (2009). Cystatin C and NT-proBNP, a powerful combination of biomarkers for predicting cardiovascular mortality in elderly patients with heart failure: results from a 10-year study in primary care. Eur. J. Heart. Fail., 11(4), 354–360. doi: 10.1093/eurjhf/hfp024
Battistoni, A., Rubbatu, S., Volpe, M. (2012). Circulating biomarkers with preventive, diagnostic and prognostic implications in cardiovascular diseases. Int J Cardiol, 157(2), 160–8. doi: 10.1016/j.ijcard.2011.06.066
Toft, I., Solbu, M., Kronborg, J., Mathisen, U. D., Eriksen, B. O., Storhaug, H. et al. (2012). Cystatin C as a risk factor cardiovascular events and all-cause mortality in the general population. Nephrol Dial Transplant, 27(7), 2780–7. doi: 10.1093/ndt/gfr751.
Raznatovska, O. M., Khudiakov, G. V. (2018). Factors of chemoresistant pulmonary tuberculosis progression in patients receiving palliative treatment. Zaporozhye medical journal, 20, 3(108), 388–391. doi: 10.14739/2310-1210.2018.3.130829
(2014). Ukraina. MOZ. Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) medychnoi dopomohy doroslym. Tuberkulioz : nakaz MOZ Ukrainy vid 31 hrudnia 2014 r. №620 [Unified clinical protocols of primary, secondary (specialized) and tertiary (highly specialized) medical care for adults "Tuberculosis" : Order of the Ministry of Health of Ukraine from December 31 2014 №620]. [in Ukrainian].
Downloads
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)
